EUROEYES plans to spend approximately HKD 119 million to acquire ophthalmic assets in Switzerland and the UK, strengthening its presence in the European refractive surgery market

According to the Zhitong Finance APP, EUROEYES (01846) announced that on September 2, 2025 (after trading hours), its wholly-owned subsidiary EuroEyes Swiss (as the buyer), the company (as the guarantor), and Betterview Swiss (as the seller) entered into a Swiss agreement, under which EuroEyes Swiss agreed to purchase Swiss assets from Betterview Swiss for a total consideration of 12.01 million Swiss francs (approximately HKD 117 million).

On September 2, 2025 (after trading hours), the company's wholly-owned subsidiary EuroEyes UK (as the buyer) entered into a UK agreement with Betterview UK (as the seller), under which EuroEyes UK agreed to purchase, and Betterview UK agreed to sell UK assets for a total consideration of 200,000 Swiss francs (approximately GBP 184,420 and HKD 1.94886 million).

The Swiss assets include (i) seven refractive surgery medical clinics located in Zurich, Bern, Lucerne, St. Gallen, Lugano, Lausanne, and Geneva; (ii) a refractive surgery treatment operating room located in Zurich; and (iii) certain headquarters assets under the Swiss agreement, which will include the following: (a) commercial contracts, customer contracts, employment contracts, lease contracts, and past patient agreements (excluding those agreed to be retained by Betterview Swiss); (b) leased property renovations, furniture and fixtures, office equipment, medical machines/production equipment, tools, computer hardware and software; (c) intellectual property; (d) customer data; (e) personnel files, technical, operational and marketing records, manuals and guidelines; (f) liabilities under the contracts mentioned in (a) above, excluding those past patient agreements that have been agreed to be retained by Betterview Swiss.

The UK assets refer to the properties, assets, and rights used by Betterview UK in its UK business (excluding certain business debts, cash on hand or in banks, and any amounts recoverable by Betterview UK related to UK business taxes), while the UK business is the ophthalmic services business operated by Betterview UK under the names "Betterview" or "Betterview Britain" (including but not limited to laser treatment and refractive surgery).

The announcement stated that the group is primarily engaged in the refractive surgery business. The acquisition will enable the group to establish a business presence in major cities in Switzerland immediately and strengthen its position in London (one of the major markets for refractive surgery in Europe). The clinics that make up the assets have generated recurring revenue and have a solid customer base.

The board believes that the acquisition represents a strategic expansion of the group into the important European market of Switzerland and consolidates its market position in the UK, thereby expanding the group's geographical distribution of business and is expected to contribute positively to the group's long-term growth. The directors believe that the terms of the agreement are fair and reasonable, and that the acquisition is in the overall interests of the company and its shareholders